Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

191.75 -1.25 (-0.65%)
Streaming Delayed Price Updated: 10:48 AM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,048,978
Open 194.49
Bid (Size) 191.64 (4)
Ask (Size) 191.78 (2)
Prev. Close 193.00
Today's Range 191.29 - 194.99
52wk Range 135.85 - 193.91
Shares Outstanding N/A
Dividend Yield 3.09%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Stocks to Buy to Survive Another S&P 500 Crash
These three stocks to buy now will protect your portfolio if the S&P 500 crashes again regardless of whether there is a recession or not. 
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga

Performance

YTD
+19.98%
+19.98%
1 Month
+14.12%
+14.12%
3 Month
+17.07%
+17.07%
6 Month
+9.94%
+9.94%
1 Year
+26.05%
+26.05%

More News

Read More
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Via Benzinga
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Via FinancialNewsMedia
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
Via Talk Markets
Topics Stocks
Exposures US Equities
Warren Buffett's Approach To Investing In Election Years
Via Benzinga
Elliott Wave Technical Analysis: AbbVie Inc.
Via Talk Markets
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Via Benzinga
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Via Investor's Business Daily
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
7 Stocks Set for a Major Bull Run
Via InvestorPlace
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Via MarketBeat
3 High-Yield Dividend Stocks That Are Looking Super Hot
Via InvestorPlace
3 Dividend-Paying ETFs to Secure Your Passive Income Stream
Via InvestorPlace
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
Privacy Policy  |  Terms of Use  |  MNG Corporate Site Map  |  Copyright